SR-THAP is a γ-aminobutyric acid transporter 3 ( GAT3 ) inhibitor with an IC 50 of 4.9 μM, and exhibits 42-fold and 23-fold selectivity over GAT1 and GlyT1 , respectively. SR-THAP inhibits GABA uptake in mammalian cells. SR-THAP is applicable to the research of epilepsy, Alzheimer's disease and ischemic stroke.
Products | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Ischemic Stroke | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Cerebrovascular Disease | Products > Disease Areas > Epilepsy | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > GABA Receptor
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.